Killer-cell immunoglobulin-like receptor polymorphism is associated with COVID-19 outcome: Results of a pilot observational study.
COVID‐19
HLA
KIR
immunogenetics
polymorphism
Journal
HLA
ISSN: 2059-2310
Titre abrégé: HLA
Pays: England
ID NLM: 101675570
Informations de publication
Date de publication:
Aug 2024
Aug 2024
Historique:
revised:
18
07
2024
received:
09
03
2024
accepted:
31
07
2024
medline:
16
8
2024
pubmed:
16
8
2024
entrez:
16
8
2024
Statut:
ppublish
Résumé
The pathogenesis of COVID-19 warrants unravelling. Genetic polymorphism analysis may help answer the variability in disease outcome. To determine the role of KIR and HLA polymorphisms in susceptibility, progression, and severity of SARS-CoV-2 infection, 458 patients and 667 controls enrolled in this retrospective observational study from April to December 2020. Mild/moderate and severe/death study groups were established. HLA-A, -B, -C, and KIR genotyping were performed using the Lifecodes® HLA-SSO and KIR-SSO kits on the Luminex® 200™ xMAP fluoroanalyser. A probability score using multivariate binary logistic regression analysis was calculated to estimate the likelihood of severe COVID-19. ROC analysis was used to calculate the best cut-off point for predicting a worse clinical outcome with high sensitivity and specificity. A p ≤ 0.05 was considered statistically significant. KIR AA genotype protected positively against severity/death from COVID-19. Furthermore, KIR3DL1, KIR2DL3 and KIR2DS4 genes protected patients from severe forms of COVID-19. KIR Bx genotype, as well as KIR2DL2, KIR2DS2, KIR2DS3 and KIR3DS1 were identified as biomarkers of severe COVID-19. Our logistic regression model, which included clinical and KIR/HLA variables, categorised our cohort of patients as high/low risk for severe COVID-19 disease with high sensitivity and specificity (Se = 94.29%, 95% CI [80.84-99.30]; Sp = 84.55%, 95% CI [79.26-88.94]; OR = 47.58, 95%CI [11.73-193.12], p < 0.0001). These results illustrate an association between KIR/HLA ligand polymorphism and different COVID-19 outcomes and remarks the possibility of use them as a surrogate biomarkers to detect severe patients in possible future infectious outbreaks.
Substances chimiques
Receptors, KIR
0
HLA Antigens
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15640Subventions
Organisme : Gerencia Regional de Salud de Castilla y Leon
ID : 2080/A/19
Organisme : Gerencia Regional de Salud de Castilla y Leon
ID : COVID 70/A/20
Informations de copyright
© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497‐506.
Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708‐1720.
Casas‐Rojo JM, Antón‐Santos JM, Millán‐Núñez‐Cortés J, et al. Clinical characteristics of patients hospitalized with COVID‐19 in Spain: results from the SEMI‐COVID‐19 registry. Rev Clin Esp. 2020;220(8):480‐494.
Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019‐nCoV) infections among travellers from Wuhan, China, 20 28 January 2020. Eurosurveillance. 2020;25(5):2000062.
Littera R, Chessa L, Deidda S, et al. Natural killer‐cell immunoglobulin‐like receptors trigger differences in immune response to SARS‐CoV‐2 infection. PLoS One. 2021;16(8 August):1‐22.
Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS‐CoV‐2 pneumonia in Wuhan, China: a single‐centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475‐481.
Jurado A, Martín MC, Abad‐Molina C, et al. COVID‐19: age, Interleukin‐6, C‐reactive protein, and lymphocytes as key clues from a multicentre retrospective study. Immun Ageing. 2020;17(1):22.
Martín MC, Jurado A, Abad‐Molina C, et al. The age again in the eye of the COVID‐19 storm: evidence‐based decision making. Immun Ageing. 2021;18(1):1‐18.
Gottlieb M, Sansom S, Frankenberger C, Ward E, Hota B. Clinical course and factors associated with hospitalization and critical illness among COVID‐19 patients in Chicago, Illinois. Jang T, ed. Acad Emerg Med. 2020;27(10):963‐973.
Jordan RE, Adab P, Cheng KK. Covid‐19: risk factors for severe disease and death. BMJ. 2020;368:m1198.
Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid‐19. N Engl J Med. 2020;382(25):e102.
Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid‐19. N Engl J Med. 2020;383(2):120‐128.
Latz CA, DeCarlo C, Boitano L, et al. Blood type and outcomes in patients with COVID‐19. Ann Hematol. 2020;99(9):2113‐2118.
Bhattacharjee S, Banerjee M, Pal R. ABO blood groups and severe outcomes in COVID‐19: a meta‐analysis. Postgrad Med J. 2022;98(e2):e136‐e137.
Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934‐943.
Marcos M, Belhassen‐García M, Sánchez‐Puente A, et al. Development of a severity of disease score and classification model by machine learning for hospitalized COVID‐19 patients. Ashkenazi I, ed. PLoS One. 2021;16(4):e0240200.
Gold JAW, Wong KK, Szablewski CM, et al. Characteristics and clinical outcomes of adult patients hospitalized with COVID‐19 – Georgia, March 2020. MMWR Morb Mortal Wkly Rep. 2020;69(18):545‐550.
Naouri D, Vuagnat A, Beduneau G, et al. Trends in clinical characteristics and outcomes of all critically ill COVID‐19 adult patients hospitalized in France between March 2020 and June 2021: a national database study. Ann Intensive Care. 2023;13(1):1‐9.
Langton DJ, Bourke SC, Lie BA, et al. The influence of HLA genotype on the severity of COVID‐19 infection. Hla. 2021;98(1):14‐22.
Augusto DG, Murdolo LD, Chatzileontiadou DSM, et al. A common allele of HLA is associated with asymptomatic SARS‐CoV‐2 infection. Nature. 2023;620(7972):128‐136.
Anzurez A, Naka I, Miki S, et al. Association of HLA‐DRB1*09:01 with severe COVID‐19. Hla. 2021;98(1):37‐42.
Weiner J, Suwalski P, Holtgrewe M, et al. Increased risk of severe clinical course of COVID‐19 in carriers of HLA‐C*04:01. eClinicalMedicine. 2021;40:101099.
Tomita Y, Ikeda T, Sato R, Sakagami T. Association between HLA gene polymorphisms and mortality of COVID‐19: an in silico analysis. Immun Inflamm Dis. 2020;8(4):684‐694.
Shkurnikov M, Nersisyan S, Averinskaya D, et al. HLA‐A*01:01 allele diminishing in COVID‐19 patients population associated with non‐structural epitope abundance in CD8+ T‐cell repertoire. PeerJ. 2023;11:e14707.
Shkurnikov M, Nersisyan S, Jankevic T, et al. Association of HLA class I genotypes with severity of coronavirus disease‐19. Front Immunol. 2021;12:641900.
Pretti MAM, Galvani RG, Vieira GF, Bonomo A, Bonamino MH, Boroni M. Class I HLA allele predicted restricted antigenic coverages for spike and nucleocapsid proteins are associated with deaths related to COVID‐19. Front Immunol. 2020;11:11.
Li J, Zaslavsky M, Su Y, et al. KIR + CD8 + T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID‐19. Science. 2022;376(6590):eabi9591.
National Research Project for SARS, Beijing Group. The involvement of natural killer cells in the pathogenesis of severe acute respiratory syndrome. Am J Clin Pathol. 2004;121(4):507‐511.
Jiang M, Guo Y, Luo Q, et al. T‐cell subset counts in peripheral blood can Be used as discriminatory biomarkers for diagnosis and severity prediction of coronavirus disease 2019. J Infect Dis. 2020;222(2):198‐202.
Wang F, Nie J, Wang H, et al. Characteristics of peripheral lymphocyte subset alteration in COVID‐19 pneumonia. J Infect Dis. 2020;221(11):1762‐1769.
Bordoni V, Sacchi A, Cimini E, et al. An inflammatory profile correlates with decreased frequency of cytotoxic cells in coronavirus disease 2019. Clin Infect Dis. 2020;71(16):2272‐2275.
Alter G, Rihn S, Walter K, et al. HLA class I subtype‐dependent expansion of KIR3DS1 + and KIR3DL1 + NK cells during acute human immunodeficiency virus type 1 infection. J Virol. 2009;83(13):6798‐6805.
Habegger de Sorrentino A, Sinchi JL, Marinic K, López R, Iliovich E. KIR‐HLA‐A and B alleles of the Bw4 epitope against HIV infection in discordant heterosexual couples in Chaco Argentina. Immunology. 2013;140(2):273‐279.
Vidal‐Castiñeira JR, López‐Vázquez A, Martínez‐Borra J, et al. Diversity of killer cell immunoglobulin‐like receptor (KIR) genotypes and KIR2DL2/3 variants in HCV treatment outcome. Björkström NK, ed. PLoS One. 2014;9(6):e99426.
Ursu LD, Calenic B, Diculescu M, Dima A, Stoian IT, Constantinescu I. Clinical and histopathological changes in different KIR gene profiles in chronic HCV Romanian patients. Int J Immunogenet. 2021;48(1):16‐24.
Mozer‐Lisewska I, Zwolińska K, Kowala‐Piaskowska AE, et al. Genetic (KIR, HLA‐C) and some clinical parameters influencing the level of liver enzymes and early virologic response in patients with chronic hepatitis C. Arch Immunol Ther Exp (Warsz). 2016;64(1):65‐73.
Clinical management of COVID‐19: Living guideline. World Health Organization; 2022:186 https://www.ncbi.nlm.nih.gov/books/NBK582435/
Yawata M, Yawata N, Draghi M, Little AM, Partheniou F, Parham P. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med. 2006;203(3):633‐645.
Biassoni R, Falco M, Cambiaggi A, et al. Amino acid substitutions can influence the natural killer (NK)‐mediated recognition of HLA‐C molecules. Role of serine‐77 and lysine‐80 in the target cell protection from lysis mediated by “group 2” or “group 1” NK clones. J Exp Med. 1995;182(2):605‐609.
Campbell KS, Purdy AK. Structure/function of human killer cell immunoglobulin‐like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology. 2011;132(3):315‐325.
Stern M, Ruggeri L, Capanni M, Mancusi A, Velardi A. Human leukocyte antigens A23, A24, and A32 but not A25 are ligands for KIR3DL1. Blood. 2008;112(3):708‐710.
Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010;116(14):2411‐2419.
Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32‐35.
Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29‐36.
Silva MJA, Rodrigues YC, Lima KVB, Lima LNGC. Innate immunity to SARS‐CoV‐2 infection: a review. Epidemiol Infect. 2022;150:e142.
Kim S, Poursine‐Laurent J, Truscott SM, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 2005;436(7051):709‐713.
Long EO, Sik Kim H, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol. 2013;31(1):227‐258.
Hsu KC, Chida S, Geraghty DE, Dupont B. The killer cell immunoglobulin‐like receptor (KIR) genomic region: gene‐order, haplotypes and allelic polymorphism. Immunol Rev. 2002;190(1):40‐52.
Vierra‐Green C, Roe D, Hou L, et al. Allele‐level haplotype frequencies and pairwise linkage disequilibrium for 14 KIR Loci in 506 European‐American Individuals. Tang J, ed. PLoS One. 2012;7(11):e47491.
Bernal E, Gimeno L, Alcaraz MJ, et al. Activating killer‐cell immunoglobulin‐like receptors are associated with the severity of coronavirus disease 2019. J Infect Dis. 2021;224(2):229‐240.
Hajeer A, Jawdat D, Massadeh S, et al. Association of KIR gene polymorphisms with COVID‐19 disease. Clin Immunol. 2022;234(August 2021):108911.
Ligotti ME, Aiello A, Accardi G, et al. Distribution of KIR genes and their HLA ligands in different viral infectious diseases: frequency study in Sicilian population. Int J Mol Sci. 2022;23(24):15466.
Maruthamuthu S, Rajalingam K, Kaur N, et al. Individualized constellation of killer cell immunoglobulin‐like receptors and cognate HLA class I ligands that controls natural killer cell antiviral immunity predisposes COVID‐19. Front Genet. 2022;13(February):1‐12.
Wang R, Sun Y, Kuang BH, et al. HLA‐Bw4 in association with KIR3DL1 favors natural killer cell‐mediated protection against severe COVID‐19. Emerg Microbes Infect. 2023;12(1):1‐18.
Jackson E, Zhang CX, Kiani Z, et al. HIV exposed seronegative (HESN) compared to HIV infected individuals have higher frequencies of telomeric Killer Immunoglobulin‐like Receptor (KIR) B motifs; contribution of KIR B motif encoded genes to NK cell responsiveness. Ansari AA, ed. PLoS One. 2017;12(9):e0185160.